Michael R.L. Stratford

A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.

Afshin Dowlati, Kelly M. Robertson, Matthew M. Cooney et al. · PubMed · 2002 · 406 citations

Medicine, Oncology, Pharmacology +17

Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results

Gordon Rustin, Susan Galbraith, Helén Anderson et al. · Journal of Clinical Oncology · 2003 · 307 citations

Pharmacy, Pharmacology, Pharmacotherapy +13

Phase I Trial of the Antivascular Agent Combretastatin A4 Phosphate on a 5-Day Schedule to Patients With Cancer: Magnetic Resonance Imaging Evidence for Altered Tumor Blood Flow

James Stevenson, Mark Rosen, Weijing Sun et al. · Journal of Clinical Oncology · 2003 · 293 citations

Medicine, Oncology, Pharmacology +17

The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia

Thomas M. Ashton, Emmanouil Fokas, Leoni A. Kunz‐Schughart et al. · Nature Communications · 2016 · 253 citations · Full text

Medicine, Oncology, Pharmacology +14

Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial

Paul Lyon, Michael Gray, Christophoros Mannaris et al. · The Lancet Oncology · 2018 · 232 citations · Full text

Pharmacy, Oncology, Pharmacology +17